Xenetic Biosciences, Inc. filed a Current Report on Form 8-K on November 13, 2026, announcing third-quarter financial results for the three months ended September 30, 2026, and disclosing strategic business updates including a proposed share exchange transaction with Santersus AG.

Key Highlights

  • Quarterly results announced: Xenetic Biosciences issued a press release on November 13, 2026, covering results for the three months ended September 30, 2026.
  • Proposed transaction disclosed: The filing references a proposed share exchange transaction with Santersus AG, described as the "Proposed Transaction."
  • Nasdaq listing risk noted: The filing identifies risk that the combined company may be unable to maintain compliance with Nasdaq listing requirements following closing, potentially requiring a reverse stock split.
  • Exchange ratio adjustment risk: The filing states that adjustments to the exchange ratio could result in Xenetic or Santersus stockholders owning more or less of the combined company than currently anticipated.
  • DNase platform highlighted: Strategic updates reference the DNase platform and an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy at the Ichilov Center in Israel.
  • Press release furnished, not filed: Exhibit 99.1, containing the full press release, is furnished and "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Xenetic Biosciences Discloses Q3 2026 Results and Santersus Share Exchange Details

Xenetic Biosciences, Inc. (NASDAQ:XBIO), headquartered at 945 Concord Street, Framingham, Massachusetts, filed an 8-K on November 13, 2026, under Item 2.02 (Results of Operations and Financial Condition). According to the filing, the company issued a press release on that date announcing results for the three months ended September 30, 2026, along with what the filing characterizes as "strategic business updates." The full text of the press release is attached as Exhibit 99.1 and incorporated by reference into Item 2.02.

The filing prominently discloses the proposed share exchange transaction with Santersus AG. Among the risks identified, the company cited the possibility that stockholder approval may not be obtained in a timely manner, that the exchange ratio may be adjusted, and that the combined company may face difficulties maintaining Nasdaq listing compliance after closing. The filing also notes risks related to obtaining sufficient additional capital and the ability of the combined company to advance product candidates, including those related to the DNase platform targeting neutrophil extracellular traps (NETs) in cancer progression.

The filing is marked as soliciting material pursuant to Rule 14a-12 under the Exchange Act and directs investors to Xenetic's Proxy Statement and other regulatory filings for additional information about the Proposed Transaction. The forward-looking statements contained in the filing and press release are described by the company as subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and the company expressly cautions that actual results could differ materially from those stated.

What Was Disclosed

Xenetic Biosciences filed an 8-K on November 13, 2026, furnishing a press release with Q3 2026 results for the period ended September 30, 2026, and disclosing strategic updates including a proposed share exchange with Santersus AG and associated risks.